首页|Accelerated national lot release on COVID-19 vaccines in Republic of Korea
Accelerated national lot release on COVID-19 vaccines in Republic of Korea
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Independent quality testing of samples from vaccine lots is part of quality assurance, especially to ensure the consistency of production lot by lot. Effective national lot release system that ensures the quality of each lot of vaccine before it is on the market is important because vaccines are intended to healthy people. In order to respond more quickly to public health crises such as the COVID-19 pandemic, the MFDS implements accelerated national lot release for rapid vaccination in Republic of Korea. For the accelerated system, improvement has been made in terms of timing of application for lot release and required documents. In addition, the processing period has been shortened and sampling method and test items have been streamlined. A thorough preparation for accelerated lot release has been developed by establishing test methods for a new platform in advance. As a result, a total of 43.88 million doses have been released within eight days on average. The accelerated lot release system has contributed significantly to rapid COVID-19 vaccination in Korea.
COVID-19PandemicCOVID-19 vaccineAdenovirus-vectoredmRNAAccelerated national lot release
Yang, Misook、Lee, Naery、Ju, Jung Hun、Park, In-Sook、Hong, Jin Tae、Oh, Ho Jung
展开 >
Ministry of Food & Drug Safety (MFDS), Republic of Korea,Minist Food & Drug Safety
NSTL
Elsevier
